RxDoctor Payments Data

Omer Iqbal, MD

Clinical Cardiac Electrophysiology · Saint Paul, MNNPI 1386807824

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,352 of the $7,683 with a category attached, or 69.7%. 4 manufacturers reported payments, led by Medtronic at 56.5% of the total. Reporting peaked in 2019 at $4,389 and has fallen 81.2% since, to $825 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MN, where the typical reported total is $10,629.

$7,683in general payments, 2019–2025

Across 58 payments — averaging $132.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$3K
  • Biotronik Inc.$73
  • Pfizer$15

What the payments were for

  • Consulting fees$4756%
  • Travel & lodging$5,35270%
  • Food & beverage$1,85624%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)33$4,338
Boston Scientific19$3,257
Biotronik Inc.5$73
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,683 in reported general payments places this provider in the 40th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

See all clinical cardiac electrophysiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$128,470
Medicare patients
960
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$83,930
XareltoRivaroxaban42$39,022
Metoprolol Succinate144$2,388
SotalolSotalol Hcl82$1,706
Flecainide Acetate40$1,257
Amiodarone Hcl42$1,087
Digoxin14$386
Carvedilol15$196
Losartan Potassium16$175
Metoprolol Tartrate20$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$83,93067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

Other clinical cardiac electrophysiology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →